Attached files

file filename
EX-10.25 - EXHIBIT 10.25 - Timber Pharmaceuticals, Inc.tm215519d1_ex10-25.htm
EX-32.2 - EXHIBIT 32.2 - Timber Pharmaceuticals, Inc.tm215519d1_ex32-2.htm
EX-31.2 - EXHIBIT 31.2 - Timber Pharmaceuticals, Inc.tm215519d1_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - Timber Pharmaceuticals, Inc.tm215519d1_ex31-1.htm
EX-23.1 - EXHIBIT 23.1 - Timber Pharmaceuticals, Inc.tm215519d1_ex23-1.htm
EX-21.1 - EXHIBIT 21.1 - Timber Pharmaceuticals, Inc.tm215519d1_ex21-1.htm
EX-10.29 - EXHIBIT 10.29 - Timber Pharmaceuticals, Inc.tm215519d1_ex10-29.htm
EX-10.28 - EXHIBIT 10.28 - Timber Pharmaceuticals, Inc.tm215519d1_ex10-28.htm
EX-10.27 - EXHIBIT 10.27 - Timber Pharmaceuticals, Inc.tm215519d1_ex10-27.htm
EX-10.26 - EXHIBIT 10.26 - Timber Pharmaceuticals, Inc.tm215519d1_ex10-26.htm
EX-4.6 - EXHIBIT 4.6 - Timber Pharmaceuticals, Inc.tm215519d1_ex4-6.htm
10-K - FORM 10-K - Timber Pharmaceuticals, Inc.tm215519d1_10k.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, John Koconis, Chief Executive Officer of Timber Pharmaceuticals, Inc. (the “Company”), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the best of my knowledge, the Company’s Annual Report on Form 10-K for the period ended December 31, 2020 (the “Report”) filed with the Securities and Exchange Commission:

 

·Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

·The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  /s/ John Koconis
  John Koconis
  Chief Executive Officer
  (Principal Executive Officer)
  March 23, 2021